Management of Severe Microcytic Anemia from Heavy Menstrual Bleeding in a 39-Year-Old Woman
This patient requires immediate iron studies (ferritin, iron/TIBC, transferrin saturation), urgent gynecology referral for abnormal uterine bleeding evaluation, and prompt initiation of oral iron replacement therapy while awaiting results.
Immediate Diagnostic Workup
Your assessment is correct—the severe microcytic anemia (Hgb 7.4, MCV 67, MCH 18.5) with heavy irregular menses strongly suggests iron-deficiency anemia. However, complete iron studies are essential before initiating treatment 1, 2.
Required iron studies:
- Serum ferritin (most specific for iron deficiency)
- Iron and total iron-binding capacity (TIBC)
- Transferrin saturation
- Reticulocyte count
- Peripheral blood smear
Key diagnostic threshold: Low ferritin (<30 μg/L in premenopausal women) with low transferrin saturation (<20%) confirms iron-deficiency anemia 1, 2.
Critical Pitfall to Avoid
While this presentation appears straightforward, if the patient fails to respond to oral iron therapy or has elevated/normal ferritin with low transferrin saturation, consider genetic disorders of iron metabolism (iron-refractory iron deficiency anemia due to TMPRSS6 defects, or acquired sideroblastic anemia in older patients) 3, 4. These conditions present with microcytic anemia but require different management approaches.
Urgent Gynecologic Evaluation
Prompt gynecology referral is mandatory given the combination of heavy irregular menses with clots and severe anemia 5. The gynecologist should:
- Perform pelvic examination
- Order transvaginal ultrasound to evaluate for structural causes (polyps, adenomyosis, leiomyomas, endometrial hyperplasia/malignancy) 6
- Consider endometrial sampling if risk factors present (age >45 years, obesity, anovulation, failed medical management)
- Rule out endometrial hyperplasia or malignancy, which can occur even in premenopausal women 5
The hormonal studies you obtained (progesterone 0.4, estrogen 88, LH 5.3, FSH 13.5) must be interpreted based on menstrual cycle timing—FSH 13.5 is not in the postmenopausal range, so this patient is still menstruating and requires gynecologic management of her bleeding 5.
Iron Replacement Strategy
Initial Treatment: Oral Iron
Start oral iron supplementation immediately (ferrous sulfate 325 mg containing 65 mg elemental iron, 2-3 times daily) 1, 2.
- Take on empty stomach for optimal absorption
- Consider adding ascorbic acid 250-500 mg twice daily to enhance absorption 1
- Continue for 3-6 months after hemoglobin normalizes to replenish iron stores 1
- Target ferritin >50 μg/L to ensure adequate stores
Monitor response: Repeat CBC in 2-4 weeks. Hemoglobin should rise by approximately 1-2 g/dL within 3-4 weeks if responding appropriately 1, 2.
When to Use Intravenous Iron
Consider intravenous iron if 1, 2:
- Hemoglobin <7 g/dL with ongoing heavy bleeding (this patient qualifies)
- Intolerance to oral iron (nausea, constipation, abdominal pain)
- Malabsorption or failure to respond to oral iron after 4-6 weeks
- Need for rapid correction before planned surgery
Available IV iron options:
- Iron dextran (Cosmofer): Can give total dose infusion (20 mg/kg over 6 hours) but carries 0.6-0.7% risk of serious reactions; requires resuscitation facilities 1
- Iron sucrose (Venofer): 200 mg bolus over 10 minutes, safer profile, requires multiple doses 1
- Ferric carboxymaltose (Ferinject): 1000 mg over 15 minutes, most convenient, similar safety to iron sucrose 1
Calculate total iron deficit: Use Ganzoni formula or similar to determine total dose needed to correct hemoglobin and replenish stores 3.
Multidisciplinary Management Approach
This patient requires coordinated care between primary care, gynecology, and potentially hematology 5:
- Gynecology: Lead role in managing abnormal uterine bleeding through hormonal therapies (combined hormonal contraceptives, levonorgestrel IUD, progestins) or antifibrinolytics (tranexamic acid) 5, 7
- Primary care: Monitor iron replacement response, manage anemia symptoms, coordinate care
- Hematology consultation if: Failure to respond to iron therapy, atypical features, or need for IV iron management 5
Additional Workup Considerations
Screen for coeliac disease with tissue transglutaminase antibodies (tTG) in all patients with iron-deficiency anemia, as it affects up to 4% of premenopausal women with IDA 1, 2.
Consider GI evaluation if:
- Age ≥50 years (this patient is 39, so not indicated unless other risk factors)
- GI symptoms present
- Family history of colorectal cancer
- Failure to respond to iron replacement after correcting menstrual losses 1, 2
Symptomatic Management
Assess for need for urgent intervention:
- If symptomatic (severe fatigue, dyspnea, chest pain, tachycardia) or actively bleeding heavily: Consider ER evaluation for possible transfusion 5
- Hemoglobin 7.4 g/dL may warrant transfusion if symptomatic, though many patients tolerate this level if chronic 5
Follow-Up Protocol
Structured follow-up schedule 1, 2:
- 2-4 weeks: Repeat CBC to confirm response to iron therapy
- 3 months: Recheck hemoglobin, ferritin to assess adequacy of replacement
- 3-monthly for 1 year: Monitor hemoglobin and red cell indices after normalization
- Annual thereafter: If stable, or sooner if symptoms recur
Continue iron supplementation for 3-6 months after hemoglobin normalizes to ensure adequate iron stores (target ferritin >50 μg/L) 1, 2.
Key Clinical Pearls
- Heavy menstrual bleeding is defined by: Clots ≥1 inch diameter, flooding (changing pad/tampon more than hourly), or duration >7 days 7
- Iron deficiency without anemia can occur—don't rely solely on hemoglobin thresholds in menstruating women 8, 9
- Document menstrual history thoroughly—studies show only 46-59% of patients with iron deficiency have menstruation documented, with male providers less likely to ask 9
- Monitor for iron overload if using IV iron—keep ferritin <500 μg/L to avoid toxicity 3